查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1423565

到 2030 年药物基因体学技术市场预测：按类型、治疗领域、技术、分销管道、最终用户和地区进行的全球分析

Pharmacogenomics Technologies Market Forecasts to 2030 - Global Analysis By Type, Therapeutic Area, Technology, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球药物基因体学技术市场规模为 68 亿美元，预计预测期内复合年增长率为 10.7%，到 2030 年将达到 139 亿美元。

药物基因体学技术是指将药理学和基因组学结合，根据个体的遗传体质开发个人化医疗的领域。这些技术涉及分析个体的遗传变异如何影响他们对药物的反应。了解这些遗传变异可以帮助医疗保健提供者更好地预测一个人对特定药物的反应，确定最有效的剂量，并将副作用的风险降至最低。

根据美国癌症协会2022年报告，预计2022年美国将新增190万癌症病例，其中包括290,560例乳癌病例。

基因组技术的进步

基因组定序和分析技术的进步为市场扩张做出了重大贡献。次世代定序(NGS)、微阵列分析和生物资讯学工具使得能够对与药物反应相关的遗传变异进行更全面的分析。这些创新将增强精准医疗，最大限度地减少药物处方中的试验，并改善患者的治疗结果。

资料解释挑战

分析遗传资料很复杂。以临床实用的方式解释结果很困难，特别是考虑到涉及大量的遗传资讯。了解特定基因突变的影响以及它们如何影响药物反应需要进行高级分析。确保患者基因资讯的安全性和保密性极为重要，但却很难保证。这些都是阻碍市场成长的因素。

个人化医疗需求不断成长

药物基因体学技术透过根据个体的基因谱量身定制治疗方法，满足了对个人化医疗日益增长的需求。这种方法可以提高药物疗效、最大限度地减少副作用并优化患者剂量。人们越来越认识到个人化医疗的重要性，个人化医疗根据个人的基因谱量身订做治疗方法。这有利于药物治疗的定制，以最大限度地提高疗效并最大限度地减少副作用。

监管和报销挑战

法律规范可能没有足够的能力来处理药物基因组学，导致标准和指南的不确定性。此外，基因检测和相关服务的报销可能无法普遍获得或标准化，从而限制了某些患者的获得。遗传资料的序列测定、分析和解释需要专门的设备和专业知识，而且这个过程非常昂贵。这种成本可能会限制普及和可近性。

COVID-19 的影响：

这次疫情加速了药物基因体学的研究，并凸显了个人化医疗的重要性。了解遗传因素如何影响药物反应对于开发 COVID-19 的治疗方法和疫苗至关重要。在大流行期间，远端医疗的转变影响了基因检测和咨询的进行方式。远端医疗服务越来越多地用于基因检测和咨询，允许更广泛的访问并最大限度地减少面对面的互动。

肿瘤学领域预计在预测期内规模最大

肿瘤学预计将成为预测期内最大的市场。优点包括个人化治疗方法选择、最大限度地减少副作用、优化药物疗效、预测患者反应。这种精确的方法透过改善治疗结果、减少试验和错误、根据个别基因图谱调整治疗方法以及推动肿瘤学朝着更有效和个性化的治疗方向发展，从而提高患者的生活品质。

预计医院业在预测期内复合年增长率最高。

预计医院业在预测期内复合年增长率最高。这种精准医疗方法可以最大限度地减少副作用、提高药物疗效并优化剂量。减少试验试误并改善患者治疗效果，同时最大限度地降低医疗成本。采用这些技术的医院将受益于个人化的治疗计划、减少的副作用和简化的剂量策略，确保为患者提供更安全、更有效的护理。

比最大的地区

预计北美在预测期内将占据最大的市场占有率。高通量定序技术的发展使得分析个体遗传资讯变得更加实用且更具成本效益。这使得药物基因组学在临床实践中广泛应用。人们越来越认识到根据个体的遗传特征定制治疗方法以提高药物疗效并儘量减少副作用的重要性。

复合年增长率最高的地区：

由于医疗基础设施投资增加等多种因素，亚太地区预计在预测期内将维持最高的复合年增长率。该市场包括 DNA序列测定、微阵列技术、聚合酶炼式反应 (PCR) 和生物资讯学工具等技术，这些技术可分析遗传变异并根据个人的遗传特征定製药物开发、配方和剂量。支持决策。

免费客製化服务：

订阅此报告的客户将收到以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 技术分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球药物基因体学技术市场：按类型

  • 生物资讯软体
  • 临床决策支援系统
  • 实验室资讯管理系统
  • 药物基因组学咨询
  • 基因检测服务
  • 样品製备套件
  • 其他类型

第六章全球药物基因体学技术市场：依治疗领域

  • 神经系统疾病
  • 肿瘤学
    • 乳癌
    • 大肠直肠癌
    • 子宫颈癌
    • 肺癌
  • 免疫疾病
  • 循环系统疾病
  • 感染疾病
  • 其他治疗领域

第七章全球药物基因体学技术市场：依技术分类

  • 顺序
  • 免疫组织化学
  • 杂合反应
  • 聚合酶炼式反应 (PCR)
  • 其他技术

第八章全球药物基因体学技术市场：按分销管道划分

  • 零售药房
  • 医院药房
  • 网路药房

第九章全球药物基因体学技术市场：依最终用户分类

  • 医院
  • 诊所
  • 检查
  • 其他最终用户

第十章全球药物基因体学技术市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十一章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司简介

  • Phamatech Inc
  • BiogeniQ Inc.
  • CENTOGENE NV
  • Empire Genomics
  • ViennaLab Diagnostics GmbH
  • Thermo Fisher Scientific
  • Admera Health
  • Agena Biosciences Inc.
  • Myriad Genetics Inc.
  • Quest Diagnostics
  • Dynamic DNA Laboratories
  • Personalis Inc.
  • Coriell Life Sciences
  • Illunima Inc
  • OneOme LLC
  • QIAGEN
  • Leica Biosystems
Product Code: SMRC24799

According to Stratistics MRC, the Global Pharmacogenomics Technologies Market is accounted for $6.8 billion in 2023 and is expected to reach $13.9 billion by 2030 growing at a CAGR of 10.7% during the forecast period. Pharmacogenomics technologies refer to a field that combines pharmacology and genomics to develop personalized medicine based on an individual's genetic makeup. These technologies involve analyzing how an individual's genetic variations influence their response to medications. By understanding these genetic variations, healthcare providers can better predict how a person will respond to a particular drug, determine the most effective dosage, and minimize the risk of adverse reactions.

According to the American Cancer Society 2022 report, an estimated 1.9 million new cancer cases will be diagnosed in the United States in 2022, which includes 290,560 cases of breast cancer.

Market Dynamics:

Driver:

Advancements in genomic technologies

Progress in genomic sequencing and analysis technologies has significantly contributed to the expansion of market. Next-generation sequencing (NGS), microarray analysis, and bioinformatics tools enable more comprehensive analysis of genetic variations related to drug response. These innovations enhance precision medicine, minimizing trial and error in prescribing medications and improving patient outcomes.

Restraint:

Data interpretation challenges

Analyzing genetic data is complex. Interpreting the results in a clinically actionable way can be challenging, especially given the vast amount of genetic information involved. Understanding the implications of specific genetic variations and their impact on drug response requires sophisticated analysis. Ensuring the security and confidentiality of patient genetic information is critical but can be difficult to guarantee. These are the factors impeding the growth of the market.

Opportunity:

Increasing demand for personalized medicine

Pharmacogenomics technologies meet the rising demand for personalized medicine by tailoring treatments based on individual genetic profiles. This approach enhances drug efficacy, minimizes adverse reactions, and optimizes dosages for patients. There's a growing recognition of the importance of personalized medicine, which tailors treatments based on individual genetic profiles. It facilitates the customization of drug therapies to maximize efficacy and minimize adverse reactions.

Threat:

Regulatory and reimbursement challenges

Regulatory frameworks may not be fully equipped to handle pharmacogenomics, leading to uncertainties about standards and guidelines. Additionally, reimbursement for genetic testing and related services might not be universally available or standardized, limiting access for some patients. Sequencing, analyzing, and interpreting genetic data require specialized equipment and expertise, making the process costly. This expense can limit widespread adoption and accessibility.

Covid-19 Impact:

The pandemic has accelerated research in pharmacogenomics, emphasizing the importance of personalized medicine. Understanding how genetic factors influence drug response became crucial in developing treatments and vaccines for COVID-19. The shift towards telemedicine during the pandemic affected the way genetic testing and counseling was delivered. There's an increased use of telehealth services for genetic testing and consultations, allowing wider accessibility and minimizing in-person interactions.

The oncology segment is expected to be the largest during the forecast period

The oncology segment is expected to be the largest during the forecast period. Advantages include personalized therapy selection, minimizing adverse reactions, optimizing drug efficacy, and predicting patient response. This precision approach enhances treatment outcomes, reduces trial and error, and improves patient quality of life by matching therapies to individual genetic profiles, advancing oncology towards more effective and personalized care.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is expected to have the highest CAGR during the forecast period. This precision medicine approach minimizes adverse reactions, enhances drug efficacy, and optimizes dosage. It reduces trial-and-error prescribing, improving patient outcomes while minimizing healthcare costs. Hospitals employing these technologies benefit from personalized treatment plans, reduced side effects, and streamlined medication strategies, ensuring safer and more effective care for patients.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. The development of high-throughput sequencing techniques has made it more feasible and cost-effective to analyze an individual's genetic information. This has enabled the widespread application of pharmacogenomics in clinical settings. There's a growing recognition of the importance of tailoring medical treatments to an individual's genetic profile to enhance drug efficacy and minimize adverse reactions.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period due to various factors such as increasing investments in healthcare infrastructure. The market involves various technologies such as DNA sequencing, microarray technology, polymerase chain reaction (PCR), and bioinformatics tools, among others, which are used to analyze genetic variations and aid in drug development, prescription, and dosage determination customized to an individual's genetic profile.

Key players in the market

Some of the key players in Pharmacogenomics Technologies market include Phamatech Inc, BiogeniQ Inc., CENTOGENE N.V., Empire Genomics, ViennaLab Diagnostics GmbH, Thermo Fisher Scientific, Admera Health, Agena Biosciences Inc., Myriad Genetics Inc., Quest Diagnostics, Dynamic DNA Laboratories, Personalis Inc., Coriell Life Sciences, Illunima Inc, OneOme LLC, QIAGEN and Leica Biosystems.

Key Developments:

In April 2023, Leica Biosystems received the clearance for BOND MMR Antibody Panel, which is expected to aid customers by offering the IHC Mismatch Repair (MMR) option when screening patients with colorectal cancer who may have Lynch syndrome.

In January 2023, QIAGEN announced a strategic partnership with Helix a population genomics company to aid companion diagnostics for genetic diseases.

Types Covered:

  • Bioinformatics Software
  • Clinical Decision Support System
  • Laboratory Information Management System
  • Pharmacogenomic Consulting
  • Genetic Testing Services
  • Sample Preparation Kits
  • Other Types

Therapeutic Areas Covered:

  • Neurological Disorders
  • Oncology
  • Immunological Disorders
  • Cardiovascular Disease
  • Infectious Diseases
  • Other Therapeutic Areas

Technologies Covered:

  • Sequencing
  • Immunohistochemistry
  • In-situ Hybridization
  • Polymerase Chain Reaction (PCR)
  • Other Technologies

Distribution Channels Covered:

  • Retail Pharmacy
  • Hospital Pharmacy
  • Online Pharmacy

End Users Covered:

  • Hospitals
  • Clinics
  • Research Institute
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Pharmacogenomics Technologies Market, By Type

  • 5.1 Introduction
  • 5.2 Bioinformatics Software
  • 5.3 Clinical Decision Support System
  • 5.4 Laboratory Information Management System
  • 5.5 Pharmacogenomic Consulting
  • 5.6 Genetic Testing Services
  • 5.7 Sample Preparation Kits
  • 5.8 Other Types

6 Global Pharmacogenomics Technologies Market, By Therapeutic Area

  • 6.1 Introduction
  • 6.2 Neurological Disorders
  • 6.3 Oncology
    • 6.3.1 Breast Cancer
    • 6.3.2 Colorectal Cancer
    • 6.3.3 Cervical Cancer
    • 6.3.4 Lung Cancer
  • 6.4 Immunological Disorders
  • 6.5 Cardiovascular Disease
  • 6.6 Infectious Diseases
  • 6.7 Other Therapeutic Areas

7 Global Pharmacogenomics Technologies Market, By Technology

  • 7.1 Introduction
  • 7.2 Sequencing
  • 7.3 Immunohistochemistry
  • 7.4 In-situ Hybridization
  • 7.5 Polymerase Chain Reaction (PCR)
  • 7.6 Other Technologies

8 Global Pharmacogenomics Technologies Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Retail Pharmacy
  • 8.3 Hospital Pharmacy
  • 8.4 Online Pharmacy

9 Global Pharmacogenomics Technologies Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Clinics
  • 9.4 Research Institute
  • 9.5 Other End Users

10 Global Pharmacogenomics Technologies Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Phamatech Inc
  • 12.2 BiogeniQ Inc.
  • 12.3 CENTOGENE N.V.
  • 12.4 Empire Genomics
  • 12.5 ViennaLab Diagnostics GmbH
  • 12.6 Thermo Fisher Scientific
  • 12.7 Admera Health
  • 12.8 Agena Biosciences Inc.
  • 12.9 Myriad Genetics Inc.
  • 12.10 Quest Diagnostics
  • 12.11 Dynamic DNA Laboratories
  • 12.12 Personalis Inc.
  • 12.13 Coriell Life Sciences
  • 12.14 Illunima Inc
  • 12.15 OneOme LLC
  • 12.16 QIAGEN
  • 12.17 Leica Biosystems

List of Tables

  • Table 1 Global Pharmacogenomics Technologies Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Pharmacogenomics Technologies Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Pharmacogenomics Technologies Market Outlook, By Bioinformatics Software (2021-2030) ($MN)
  • Table 4 Global Pharmacogenomics Technologies Market Outlook, By Clinical Decision Support System (2021-2030) ($MN)
  • Table 5 Global Pharmacogenomics Technologies Market Outlook, By Laboratory Information Management System (2021-2030) ($MN)
  • Table 6 Global Pharmacogenomics Technologies Market Outlook, By Pharmacogenomic Consulting (2021-2030) ($MN)
  • Table 7 Global Pharmacogenomics Technologies Market Outlook, By Genetic Testing Services (2021-2030) ($MN)
  • Table 8 Global Pharmacogenomics Technologies Market Outlook, By Sample Preparation Kits (2021-2030) ($MN)
  • Table 9 Global Pharmacogenomics Technologies Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 10 Global Pharmacogenomics Technologies Market Outlook, By Therapeutic Area (2021-2030) ($MN)
  • Table 11 Global Pharmacogenomics Technologies Market Outlook, By Neurological Disorders (2021-2030) ($MN)
  • Table 12 Global Pharmacogenomics Technologies Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 13 Global Pharmacogenomics Technologies Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 14 Global Pharmacogenomics Technologies Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 15 Global Pharmacogenomics Technologies Market Outlook, By Cervical Cancer (2021-2030) ($MN)
  • Table 16 Global Pharmacogenomics Technologies Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 17 Global Pharmacogenomics Technologies Market Outlook, By Immunological Disorders (2021-2030) ($MN)
  • Table 18 Global Pharmacogenomics Technologies Market Outlook, By Cardiovascular Disease (2021-2030) ($MN)
  • Table 19 Global Pharmacogenomics Technologies Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 20 Global Pharmacogenomics Technologies Market Outlook, By Other Therapeutic Areas (2021-2030) ($MN)
  • Table 21 Global Pharmacogenomics Technologies Market Outlook, By Technology (2021-2030) ($MN)
  • Table 22 Global Pharmacogenomics Technologies Market Outlook, By Sequencing (2021-2030) ($MN)
  • Table 23 Global Pharmacogenomics Technologies Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 24 Global Pharmacogenomics Technologies Market Outlook, By In-situ Hybridization (2021-2030) ($MN)
  • Table 25 Global Pharmacogenomics Technologies Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 26 Global Pharmacogenomics Technologies Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 27 Global Pharmacogenomics Technologies Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 28 Global Pharmacogenomics Technologies Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 29 Global Pharmacogenomics Technologies Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 30 Global Pharmacogenomics Technologies Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 31 Global Pharmacogenomics Technologies Market Outlook, By End User (2021-2030) ($MN)
  • Table 32 Global Pharmacogenomics Technologies Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 33 Global Pharmacogenomics Technologies Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 34 Global Pharmacogenomics Technologies Market Outlook, By Research Institute (2021-2030) ($MN)
  • Table 35 Global Pharmacogenomics Technologies Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.